Bluebirdbio (NASDAQ:BLUE) a Buy or a Sell? What does Wells Fargo Think?

Share

How Wells Fargo Currently Rates Bluebirdbio (NASDAQ:BLUE)

Analysts at Wells Fargo commenced coverage coverage for shares of Bluebirdbio (NASDAQ:BLUE) in a recent report revealed on Friday morning. The investment house set a Outperform rating on the $2.89B market cap firm.

From a total of 11 analysts covering bluebird bio (NASDAQ:BLUE) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $204 while the lowest target price is $108. The mean of all analyst targets is $156.82 with a 89.59% above today’s ($79.03) stock price. bluebird bio was the topic of 13 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. Roth Capital initiated shares on December 3 with “Buy” rating. Morgan Stanley upgraded shares to “Overweight” rating and $143 target share price in a report from an October 5. Goldman Sachs initiated BLUE stock in a recent report from November 18 with “Buy” rating. JP Morgan maintained the rating on August 24. JP Morgan has a “Overweight” rating and a $244 price target on shares. Finally, Oppenheimer initiated the stock with “Outperform” rating in a report issued on an October 20.

Approximately 455,437 shares of stock traded hands. bluebird bio Inc (NASDAQ:BLUE) has declined 43.42% since May 1, 2015 and is downtrending. It has underperformed by 40.64% the S&P500.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has a market cap of $2.89 billion. The Firm is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. It currently has negative earnings. The Company’s products include Lenti-D, LentiGlobin and CAR T Cells.

According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.” Get a free copy of the Zacks research report on bluebird bio Inc (BLUE).

COMMENTS: